Drug Safety Evaluation in the United States of America

  • Yoon, Young-H. (Department of Toxicology and Pathology Drug Safety Evaluation, Bristol-Myers Squibb Pharmaceutical Research Institute, Bristol-Myers Squibb Company New Brunswick) ;
  • Johnson, Charles A. (Department of Toxicology and Pathology Drug Safety Evaluation, Bristol-Myers Squibb Pharmaceutical Research Institute, Bristol-Myers Squibb Company New Brunswick) ;
  • Soltys, Randolph A. (Department of Toxicology and Pathology Drug Safety Evaluation, Bristol-Myers Squibb Pharmaceutical Research Institute, Bristol-Myers Squibb Company New Brunswick) ;
  • Sibley, Peter L. (Department of Toxicology and Pathology Drug Safety Evaluation, Bristol-Myers Squibb Pharmaceutical Research Institute, Bristol-Myers Squibb Company New Brunswick)
  • Published : 1997.12.01

Abstract

General steps in the discovery and development of novel drugs in the United States are presented. The first step is the discovery of novel drugs. Brief histories and mechanisms of a few novel drugs in the American market are outlined. In this presentation preclinical animal toxicologic studies (drug safety evaluateion) are emphasized in regard to drug development. When preclinical animal studies have defined the toxicity and the doses at which it occurs an Investigational new Drug Application (IND) is submitted to the Food and Drug Administration (FDA) An IND notifies the FDA the intention to begin testing a novel drug in human subjects.

Keywords